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Abstract 
Axtra® XB 201 is a preparation of endo-1,4-beta-xylanase and endo-1,3(4)-beta-glucanase to be used 
as a feed additive for lactating sows (major and minor species) and minor porcine species for meat 
production at the recommended dose of 1,220 U xylanase and 152 U glucanase per kg feed and 
610 U xylanase and 76 U glucanase, respectively. The Panel on Additives and Products or Substances 
used in Animal Feed (FEEDAP Panel) adopted a scientific opinion on the safety and efficacy of this 
product as a zootechnical additive for poultry, piglets and pigs for fattening. Since aspects other than 
the safety and efficacy for the new target species/categories have been addressed previously, the 
current assessment addressed the safety and efficacy for the new target species only. Based on the 
results obtained in a tolerance trial in sows, the FEEDAP Panel concluded that the additive is safe for 
lactating sows at the recommended dose. The safety for piglets was previously established in a trial 
where piglets tolerated a 60-fold the recommended dose for minor porcine species for meat 
production. The Panel extrapolated the conclusions on the safety reached in major porcine species to 
minor porcine species. Seven efficacy trials in sows were submitted. In two short-term trials, the 
additive improved the apparent faecal digestibility of the dietary gross energy by the sows at the 
recommended dose. The same dose permitted to reduce the body weight loss of the sow during 
lactation in two long-term trials. Therefore, the Panel concluded that the additive has the potential to 
be efficacious in lactating sows at the recommended dose. In the previous opinion, the efficacy in 
piglets and pigs for fattening was established at the dose recommended for minor porcine species for 
meat production. The Panel extrapolated the conclusions reached in major porcine species to minor 
porcine species. 
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Summary 
Following a request from the European Commission, the Panel on Additives and Products or 
Substances used in Animal Feed (FEEDAP Panel) was asked to deliver a scientific opinion on the safety 
and efficacy of Axtra® XB 201 (endo-1,4-beta-xylanase and endo-1,3(4)-beta-glucanase) as a feed 
additive for sows for reproduction (lactating), minor porcine species for meat production and minor 
porcine species during lactation. 
The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) adopted a scientific 
opinion on the safety and efficacy of the product as a zootechnical additive (functional group of 
digestibility enhancers) for poultry, piglets and pigs for fattening. That opinion considered the safety 
aspects of the additive regarding the target species, the consumer, the user, the environment and the 
genetic modification of one of the production strains as well as its efficacy for the target species. 
Axtra® XB 201 is now proposed for use in lactating sows (including minor porcine species) at the 
minimum dose of 1,220 U xylanase and 152 U glucanase per kg feed and in minor porcine species for 
meat production at the minimum dose of 610 U xylanase and 76 U glucanase per kg feed. The Panel 
considered that aspects other than the safety and efficacy for the new target species/categories have 
been addressed in the previous opinion and is not aware of any new information that would lead it to 
reconsider the previous conclusions. Therefore, the present assessment addressed the safety and 
efficacy for the new target categories/species only. 
A tolerance trial showed that sows tolerated well a 10-fold overdose of the recommended dose and 
therefore the FEEDAP Panel concluded that the additive is safe for lactating sows at that dose. The 
safety of the product in piglets was previously established in a trial where piglets tolerated well a 
60-fold the dose that is now recommended for minor porcine species for meat production. Based on 
the margin of safety shown by the product in the trials performed in sows and piglets, the Panel 
considered that the conclusion can be extrapolated to minor porcine species at the corresponding 
dose. 
Seven efficacy trials were assessed, three short-term trials and four long-term trials. In two short-term 
trials, the additive improved the apparent faecal digestibility of the dietary gross energy in lactating 
sows at the recommended dose. The same dose permitted to reduce the body weight loss of the sow 
during lactation in two long-term trials, without having a negative impact on the litter performance. 
Consequently, the FEEDAP Panel considered that the additive has the potential to be efficacious at 
that dose. The efficacy of the product in piglets and pigs for fattening was established previously at 
the dose that is now recommended for minor porcine species for meat production. Considering that 
the mode of action of the enzymes is well known and it is assumed to be the same among porcine 
species the conclusions drawn in the major porcine species were extrapolated to minor porcine 
species, lactation and fattening phases at the corresponding dose.  
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1. Introduction  
1.1. Background and Terms of Reference  
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7.  
The European Commission (EC) received a request from Danisco (UK) Ltd2 for authorisation of the 
product Axtra® XB 201, endo-1,4-beta-xylanase and endo-1,3(4)-beta-glucanase, when used as a 
feed additive for pigs, sows for reproduction, minor porcine species for meat production and minor 
porcine species for reproduction3 (category: zootechnical additive; functional group: digestibility 
enhancers)  
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application 
to the European Food Safety Authority (EFSA) as an application under Article 4(1) (authorisation of a 
feed additive or new use of a feed additive). EFSA received directly from the applicant the technical 
dossier in support of this application. The particulars and documents in support of the application 
were considered valid by EFSA as of 23 September 2014. 
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety 
for the target animals, consumer, user and the environment and on the efficacy of the product Axtra® 
XB 201 (endo-1,4-beta-xylanase and endo-1,3(4)-beta-glucanase), when used under the proposed 
conditions of use (see Section 3). 
1.2. Additional information  
The additive Axtra® XB 201 is a preparation of endo-1,4-beta-xylanase (xylanase: EC 3.2.1.8) 
produced by a genetically modified strain of Trichoderma reesei (ATCC PTA 5588) and endo-1,3(4)-
beta-glucanase (glucanase: EC 3.2.1.6) produced by a non-genetically modified strain of Trichoderma 
reesei (ATCC SD 2106) available in two forms, solid (TPT) and liquid (L). The additive is authorised for 
its use in poultry, piglets and pigs for fattening as a zootechnical additive, functional group of 
digestibility enhancers.  
The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) adopted a 
scientific opinion on the safety and efficacy of this product4 as a feed additive for poultry, piglets and 
pigs for fattening (EFSA FEEDAP Panel, 2010). That opinion considered the safety aspects of the 
additive regarding the consumer, the user, the environment and the genetic modification present in 
one of the production strains. Moreover, the safety and efficacy of the product for poultry, piglets and 
pigs for fattening was established.  
2. Data and Methodologies  
2.1. Data 
The present assessment is based on data submitted by the applicant in the form of a technical 
dossier5 in support of the authorisation request for the use of Axtra® XB as a feed additive. The 
technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003 
and the applicable EFSA guidance documents. 
The FEEDAP Panel used the data provided by the applicant together with data from other sources, 
such as previous risk assessments by EFSA. 
                                                          
1  Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in 
animal nutrition. OJ L 268, 18.10.2003, p. 29. 
2  Danisco (UK) Ltd, PO Box 777, SN8 1XN, Marlborough, Wilshire, UK.  
3 During the assessment the applicant requested to modify the target species as follows, sows for reproduction (lactating 
sows), minor porcine species for meat production and for reproduction (lactating sows). 
4 Formerly named as Danisco Glycosidase. 
5 FEED dossier reference: FAD-2014-0026. 
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The European Union Reference Laboratory considered that the conclusions and recommendations 
reached in the previous assessment are valid and applicable for the current application.6 
2.2. Methodologies 
The approach followed by the FEEDAP Panel to assess the safety and the efficacy of Axtra® XB is in 
line with the principles laid down in Regulation (EC) No 429/20087 and the relevant guidance 
documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012)8 and the Technical 
guidance: Tolerance and efficacy studies in target animals (EFSA FEEDAP Panel, 2011).9  
3. Assessment 
Axtra® XB 201 is proposed for use in lactating sows (including minor porcine species) in order to 
increase the digestibility of the diets and reduce the body weight loss of sows during lactation at the 
minimum dose of 1,220 U xylanase and 152 U glucanase per kg feed and in minor porcine species for 
meat production at the minimum dose of 610 U xylanase and 76 U glucanase per kg feed. The Panel 
considers that aspects other than the safety and efficacy for these target species/categories have 
been addressed in the previous opinion and is not aware of any new information that would lead it to 
reconsider the previous conclusions. Therefore, the present assessment will address the safety and 
efficacy for the new target species only.  
3.1. Safety for the target species 
3.1.1. Safety for lactating sows 
A total of 48 sows (Duroc  Landrace) from parity 1 to 8 and with a mean initial weight ~ 260 kg were 
allocated, according to body weight and parity number, to three dietary treatments (n = 16 sows, 
initial number).10 A basal diet based on wheat, barley, sugar beet pulp, wheat middlings and soya 
bean meal, was supplemented with Axtra® XB 201 (TPT) to provide (xylanase/glucanase) 0/0, 
1,220/152 (recommended dose) or 12,200/1,520 (10 recommended dose) U/kg feed. Enzyme 
recoveries in the experimental diets were confirmed by analysis. The study was performed in six 
consecutive production runs (involving nine sows in four of the runs and six in the other two runs). 
The dietary treatment started three weeks before farrowing and finished on the day piglets were 
weaned (day 28 of life). Feed was offered in mash form twice daily during the gestation period and 
thereafter ad libitum. Sows were weighed at the start, at the transfer to the farrowing crate, after 
farrowing and at piglets’ weaning and weight gain/loss was calculated. Individual feed intake of the 
sows was monitored throughout the study. Litter size was recorded at birth and then standardised to 
11‒12 piglets per sow at 24 h post-farrowing. Piglets were weighed at 24 h of life, 14 days and at 
weaning. Blood sampling was performed on eight sows in total at allocation to the treatments and on 
12 sows per treatment after weaning. Samples were analysed for haematological11 and biochemical12 
parameters. An analysis of variance (ANOVA) was performed on the data obtained, considering the 
sow as the experimental unit. The effect of the run, sow’s parity number and treatment were 
considered in the model. Means were compared using the Student–Newman–Keuls test. 
No sows died during the study but three sows were excluded from the study, one sow from the 
control due to an early farrowing and two from the 10-fold dose due to early farrowing and problems 
                                                          
6 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/default/files/FinRep-FAD-2010-0007.pdf 
7  Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No 
1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and 
the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1. 
8  EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2012. Guidance for the 
preparation of dossiers for zootechnical additives. EFSA Journal 2012;10(1):2536, 19 pp. doi:10.2903/j.efsa.2012.2536 
9  EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2011. Technical guidance: 
Tolerance and efficacy studies in target animals. EFSA Journal 2011;9(5):2175, 15 pp. doi:10.2903/j.efsa.2011.2175 
10 Technical dossier/Section III/Annex III.2 and Supplementary information February 2015 and July 2015. 
11 Including: haematocrit, red blood cells, mean corpuscular volume, anisocytosis index, mean corpuscular haemoglobin, mean 
corpuscular haemoglobin concentration, white blood cells (including lymphocytes, segmented neutrophil, monocytes, 
eosinophils). 
12 Including: total protein, albumin, urea, plasma urea nitrogen, glucose, alanine aminotransferase, aspartate aminotransferase, 
gamma-glutamyl transpeptidase, alkaline phosphatase. 
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during the lactation. The overall piglet’s mortality reached 19%. The mortality was mostly found 
during the first 24 h (13–16%), probably as a consequence of the high initial number of piglets per 
sow (13.3 piglets born/sow), but there were no differences between treatments. Mean feed intake of 
the sows was 4.1 kg/day (for the overall period) and sow’s weight loss between farrowing and 
weaning was ~ 30 kg and no statistically significant differences were found between treatments. 
Haematological profile and biochemical blood parameters of the sows at weaning were not 
significantly different between treatments. Mean number of weaned piglets was 11 and piglet’s daily 
body weight gain was 220 g, no statistically significant differences were found between treatments.  
Therefore, the FEEDAP Panel considers that the additive AXTRA® XB 201 is safe for lactating sows at 
the recommended dose. 
3.1.2. Safety for minor porcine species  
The tolerance study in sows showed that the sows tolerate well a 10-fold the dose of 1,220 U 
xylanase and 152 U glucanase per kg feed. 
The applicant submitted a tolerance trial in weaned piglets that was evaluated by the FEEDAP Panel in 
2010 in which the piglets tolerated well 15-fold the dose of 2,440 U xylanase and 304 U glucanase per 
kg feed (representing 60-fold the recommended dose for minor porcine species for meat 
production).13 The FEEDAP Panel concluded based on that trial that the additive is safe for piglets and 
pigs for fattening at that dose.  
Considering the margin of safety shown in major porcine species, the FEEDAP Panel considers that the 
conclusions on the safety of the product can be extrapolated to minor porcine species for meat 
production at 610 U xylanase and 76 U glucanase per kg feed and in lactating sows at 1,220 U 
xylanase and 152 U glucanase per kg feed. 
3.2. Efficacy 
3.2.1. Efficacy for lactating sows 
Short-term trials 
Three short-term trials performed with lactating sows were submitted. The details on the design and 
the relevant results are presented in Table 1. In the three trials, lactating sows were fed with one of 
the two dietary treatments: diet without additive (control) or diet supplemented with Axtra® XB 201 to 
provide 1,220 xylanase U and 152 glucanase U/kg feed. Enzyme activities in the diets were confirmed 
by analyses. In order to study the digestibility of dietary energy and of nutrients, external markers 
were added to the diets: HCl-insoluble ash in trial 1 and 3 or titanium dioxide in trial 2. Faecal samples 
were collected at least two weeks after the start of the treatment. The study of the faecal apparent 
digestibility included, in all trials, gross energy, dry/organic matter, crude protein, crude fibre, neutral 
detergent fibre (NDF) and acid detergent fibre (ADF). The faecal apparent digestibility of lignin, 
hemicellulose, cellulose was studied in trial 1, that for non-starch polysaccharides (NSP, as total and 
individual sugars) was studied in trial 1 and 3 and that for crude fat, P and Ca in trial 3. An ANOVA 
was performed with the data obtained. Differences were considered significant at a level of at least 
P < 0.05. 
  
                                                          
13 Technical dossier/Section III/Annex II.1. 
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Table 1:  Design of the short-term trials performed in lactating sows and results on the digestibility 
of the energy of the diets 
Trial N per 
treatment 
(body 
weight) 
breed 
Start of  
treatment 
Start of 
collection 
(duration) 
methodology 
Basal diet AXTRA® XB 201 
xylanase/glucanase 
(U/kg feed) 
Digestibility 
of the 
energy 
(%) 
114 16 
295 kg 
Duroc x 
Landrace 
Three 
weeks 
before 
farrowing 
Day 18 
lactation 
(3 days) 
Spot sampling 
Wheat, barley, 
sugar beet pulp, 
wheat middlings 
and soya bean 
meal 
0/0 
1,220/152 
73.5 
77.2* 
215 9 
284kg 
Hybrid 
Day 108 
gestation 
Day 12 
lactation 
(3 days) 
Rectum 
Wheat and 
barley 
0/0 
1,220/152 
80.8 
84.0* 
316 13 
221 kg 
Large 
White x 
Landrace 
Two weeks 
before 
farrowing 
Day 28 
lactation 
(1 day) 
Not reported 
Wheat, barley, 
sugar beet pulp 
and wheat 
middlings 
0/0 
1,220/152 
84.3 
84.8 
* Mean values within one row are different to control (P < 0.05) 
 
Supplementation of the diets with Axtra® XB 201 increased significantly the apparent faecal 
digestibility of energy in trial 1 and 2, but not in trial 3 (Table 1). The results showed also that the 
additive increased significantly the apparent faecal digestibility of NDF (trial 1: 60.0 vs 66.2%; trial 2: 
60.2 vs 67.4%), ADF (trial 1: 44.1 vs 54.0%; trial 2: 44.9 vs 53.9%), crude fibre (trial 2: 41.3 vs 
56.6%; trial 3: 28.8 vs 37.0%), lignin (trial 1: 30.0 vs 40.0%), cellulose (trial 1: 49.8 vs 59.4%), NSP 
(trial 1: 55.7 vs 63.2% for total NSP), crude protein (trial 2: 83.1 vs 86.2%), organic matter (trial 2: 
83.5 vs 86.6%) and calcium (trial 3: 56.5 vs 64.1%). 
Long-term trials 
Four long-term trials were submitted, the details on the design are presented in Table 2. Trials 1, 3 
and 4 considered two dietary treatments; diet without additive (control) or diet supplemented with 
Axtra® XB 201 to provide 1,220 xylanase U and 152 glucanase U/kg feed. Trial 2 followed a 2 x 2 
design with two different basal diets differing in the amount of fibre and two levels of additive 
supplementation, not supplemented or supplemented with Axtra® XB 201 to provide 1,220 xylanase U 
and 152 glucanase U/kg feed. Enzyme activities in the diets were confirmed by analyses. The start of 
the treatments was at the end of gestation and followed during lactation. The duration was of at least 
39 days. In trials 1 and 2, feed was offered ad libitum throughout the study, and in trials 3 and 4, it 
was offered restrictively during gestation and then in the lactation, the allowance was set at 6.5 kg 
per day in trial 3 or offered ad libitum in trial 4. Feed intake of the sows was monitored throughout 
the experimental period and sows were weighed after farrowing and at weaning of the piglets in all 
trials. In trials 2 to 4, the back-fat thickness was measured after farrowing and at weaning (P2 
position, at 6–8 cm of the dorsal midline at the last rib curve). Weight and back-fat loss during the 
lactation was calculated, where relevant. In trial 4, the weaning to oestrus interval of the sows was 
also recorded. Regarding the litters’ parameters, number of piglets and weight was recorded at 
farrowing, after cross-fostering and at weaning. Cross-fostering was performed during the first 24 h of 
life and within treatment. An ANOVA was performed with the data obtained considering the effect of 
the diet and parity number of the sows. In trial 2, the two main effects and their interaction was 
considered in the model. For the sow’s body weight loss during lactation, the weight at farrowing was 
also considered as a covariate in the model. Differences were considered significant at a level of at 
least P < 0.05. 
                                                          
14 Technical dossier/Section IV/Annex IV.13. 
15 Technical dossier/Section IV/Annex IV.14. 
16 Technical dossier/Section IV/Annex IV.15. 
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Table 2:  Design of the long-term trials performed in lactating sows  
Trial N per 
treatment 
Breed 
(parity 
number) 
Basal diet Treatment 
Start End 
117 15 
Duroc x 
Landrace 
(1–8) 
Wheat, barley, rapeseed meal 
and soya bean meal 
Day 97 of 
gestation 
Day 27 
lactation 
218 10 
Hybrid 
(1–8) 
Low fibre: wheat and barley 
Day 108 
gestation 
Day 27 
lactation 
High fibre: wheat, barley, wheat 
bran, corn distillers, sunflower 
meal and soya hulls 
319 13 
Large White x 
Landrace 
(1–7) 
Wheat, barley, sugar beet pulp 
and wheat middlings 
Day 100 
gestation 
Day 28 
lactation 
420 29 
Large White x 
Landrace 
(1–8) 
Wheat, barley and soya bean 
meal 
Day 93 
gestation 
Day 18 
lactation 
 
No sows died. Table 3 shows the results of the sow’s daily feed intake, body weight loss and back-fat 
loss of the sows during lactation. Average feed intake of the sows was not significantly different 
between treatments in any of the studies. In trials 1 and 4, sows receiving the additive lost 
significantly less body weight from farrowing to weaning than those receiving the control. In trial 2, 
the back-fat loss was significantly lower in the sows receiving the additive compared to those 
receiving the non-supplemented diet. In trial 4, no differences were found in the weaning to oestrus 
interval. The number of weaned piglets, piglets’ weight at weaning and litter weight (data not shown) 
were not significantly different between treatments (Table 4). 
Table 3:  Effect of Axtra® XB 201 on the daily feed intake, body weight and body weight loss of the 
sows from farrowing to weaning 
Trial Axtra® XB 
xylanase/glucanase 
U/kg feed 
Daily 
feed 
intake 
(kg) 
Body weight (kg) Back-fat 
loss (mm) 
Farrowing Weaning Loss(a) 
1 
0/0 4.69 258 225 32.6 (31.0) Not 
measured 1,220/152 4.25 243 217 25.7* (24.2*) 
2 
Low Fibre 0/0 5.13 254 231 22.7 4.0 
Low Fibre 1,220/152 5.12 266 248 18.3 2.6* 
High Fibre 0/0 5.38 262 241 20.6 5.0 
High Fibre 1,220/152 5.42 256 239 17.1 3.5* 
3 
0/0 6.74 205 209 - 0.82 
1,220/152 6.51 202 203 - 0.70 
4 
0/0 5.36 248 239 8.4 (9.6) 2.56 
1,220/152 5.57 238 237 0.2* (2.9*) 2.51 
*  Within one trial and within a column, mean value is different to control (P < 0.05). 
(a): Values within brackets show the body weight loss when the statistical analysis considered the initial body weight of the 
sows. For trial 2, the values considering the covariate were only made available for the main effect of diet. 
 
  
                                                          
17 Technical dossier/Section IV/Annex IV.9 and Supplementary information July 2015/Annex 2. 
18 Technical dossier/Section IV/Annex IV.10 and Supplementary information July 2015/Annex 3. 
19 Technical dossier/Section IV/Annex IV.11. 
20 Technical dossier/Section IV/Annex IV.12 and Supplementary information July 2015 Annex 4. 
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Table 4:  Effect of Axtra® XB 201 on litter size, piglets’ weight and mortality during lactation 
Trial Axtra® XB 
xylanase/glucanase U/kg 
feed 
Litter Size (n)  Piglets’ weight 
(kg) 
Mortality 
% 
Initial(a) Final(b)  Initial(a) Final(b) 
1 0/0 11.5 11.0  1.51 7.65 4.6 
1,220/152 11.4 10.6  1.58 7.47 7.6 
2 Low Fibre 0/0 13.7 10.8  1.52 7.91 20.9 
Low Fibre 1,220/152 11.5 9.7  1.60 8.63 14.7 
High Fibre 0/0 11.2 9.6  1.62 7.86 12.4 
High Fibre 1,220/152 12.3 10.1  1.48 8.02 17.4 
3 0/0 12.9 11.2  1.40 7.45 13.2 
1,220/152 12.9 10.8  1.64* 7.69 16.0 
4 0/0 11.4 9.8  1.38 6.56 12.9 
1,220/152 10.4 9.5  1.46 6.44 8.2 
*  Within one trial and within one column, mean value is different to control (P < 0.05). 
(a): Initial day for trial 1, 2 and 4 is day 1 and for trial 3 is after birth. 
(b): Final day for trial 1, 2 is day 27, for trial 3 is day 28 and for trial 4 is day 18. 
Conclusion on efficacy in lactating sows 
The additive Axtra® XB 201 improved the apparent faecal digestibility of gross energy of the diets in 
two out of three short-term trials done in lactating sows. In two out of four long-term trials with 
lactating sows, Axtra® XB reduced the body weight loss during lactation. The FEEDAP Panel concludes 
that the additive has the potential to be efficacious in lactating sows at the minimum recommended 
dose.  
3.2.2. Efficacy for minor porcine species  
The data in lactating sows show that the additive has the potential to be efficacious at the dose of 
1,220 U xylanase and 152 U glucanase per kg feed. The applicant submitted the efficacy studies that 
supported the efficacy in piglets and pigs for fattening for the previous evaluation.21 From the studies 
submitted, the FEEDAP Panel concluded that the efficacy of the additive was demonstrated at the 
intended minimum recommended dose of 610 U xylanase and 76 U glucanase per kg feed. 
The mode of action of the enzymes is well known and it is assumed to be the same among porcine 
species. Therefore, the Panel considers that the conclusions reached on the efficacy for the major 
porcine species can be extrapolated to minor porcine species at the dose of 1,220 U xylanase and 152 
U glucanase per kg feed in the lactation phase and at 610 U xylanase and 76 U glucanase per kg feed 
for the weaning–fattening phase.  
3.3. Post-market monitoring 
The FEEDAP Panel considers that there is no need for specific requirements for a post-market 
monitoring plan other than those established in the Feed Hygiene Regulation22 and Good 
Manufacturing Practice. 
4. Conclusion 
The additive is safe and efficacious for lactating sows and minor porcine species at the corresponding 
recommended doses. 
                                                          
21 Technical dossier/Section IV/Annexes IV.1 to IV.8. 
22  Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements 
for feed hygiene. OJ L 35, 8.2.2005, p. 1. 
Axtra®XB sows and minor porcine species 
 
 
 
www.efsa.europa.eu/efsajournal 11 EFSA Journal 2016;14(1):4350 
 
Documentation provided to EFSA 
1. Axtra® XB for sows and minor porcine species. August 2014. Submitted by Danisco UK Ltd. 
2. Axtra® XB for sows and minor porcine species. Supplementary information. February 2015. 
Submitted by Danisco UK Ltd. 
3. Axtra® XB for sows and minor porcine species. Supplementary information. July 2015. 
Submitted by Danisco UK Ltd. 
4. Comments from Member States. 
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